IPS
Here, we report that the IkB kinase 2 (IKK2) antagonist BAY 65-5811 or "compound A," a highly potent and specific inhibitor of the NF-kB pathway, was able to improve median survival times and recipient oxygenation in a well-described mouse model of IPS.